Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Huberman says verified, US-made sourcing would change the peptide market, and wonders which compounds beyond GLPs would qualify.
She points out one trial enrolled people with diabetes and the other excluded them, so the results aren't a head to head match.
The skincare brand suggests applying its peptide serum first for hydration, then retinal at night for anti-ageing.
The IMF addresses whether GLP-1 weight loss medications are a safe option for people with myeloma, including those with insulin resistance.
Icotrokinra became the first approved oral IL23 receptor blocker, and a trial found tirzepatide plus ixekizumab gave deeper responses.
Oral Wegovy fell to about 173,500 weekly prescriptions and Foundayo rose to 60,151. Novo also eyes 15 to 20% yearly GLP-1 growth in India.
Peptides have become a favorite of longevity and optimization podcasts, and USA TODAY looks at where those claims go wrong.
Researchers built a topology-guided add-on to AlphaFold3 aimed at the threaded tail that trips up lasso peptide structure prediction.
A lawyer named Jeff walks through how his side argues Ozempic, Wegovy and other semaglutide drugs may be linked to NAION, a serious form of sudden vision loss.
The Pennsylvania county is funding a study into whether the GLP-1 drug can help people with substance use disorders.
Amy Maxmen reports on how experimental peptides are being hyped in optimization circles and where the talk goes wrong.
A personal story about the control he felt on the drug and the cravings for it that followed once he stopped.
Dr David Barzilai traced the development records of popular compounds and found many trace back to pharmaceutical companies.
Inversor Bético rates the business strongly but says entry timing isn't there yet, pointing to margins squeezed by the move from compounded to branded GLP-1s.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Bahrain's National Health Regulatory Authority signed off on the oral GLP-1 version of Wegovy for treating obesity, per the state news agency.
Retinol speeds up cell turnover while copper peptides back skin repair and collagen and elastin production. A short skincare explainer on using both.
The Danish town that makes Ozempic and Wegovy is nicknamed Novo Town, a sign of how much these drugs have reshaped one place.
He sets semaglutide's 14.9% average weight loss in its main obesity trial against tirzepatide's 20.9% at the top dose.
Bansal notes about 21% of US households now have a GLP-1 user, up from 9% in early 2025, and says India is watching the shift in fashion closely.
Loading…